Rudolph E. Tanzi is the Joseph P. and Rose F. Kennedy Professor of Neurology at Harvard University, where his research focuses on the genetic basis of neurodegenerative conditions. Since the 1980s, he has identified genes linked to Alzheimer’s disease, Huntington’s disease, and Wilson’s disease, while pioneering new models to accelerate the development of clinical therapeutics.
Early Research and Genetic Mapping
Born in 1958 in Providence, Rhode Island, Tanzi pursued his education at the University of Rochester, earning degrees in microbiology and history in 1980. He later received his Ph.D. in neurobiology from Harvard Medical School in 1990. His career began in 1980 at Massachusetts General Hospital, where he assisted in localizing the gene for Huntington’s disease. By 1987, he was the lead author on multiple studies detailing the mapping and characterization of the amyloid beta-protein precursor gene, a fundamental component in understanding early-onset familial Alzheimer’s disease.
Twenty questions, eight minutes on the clock, and a percentile measured against everyone who has taken it. No sign-up.
Take the IQ test →Discovery of Disease Genes
Throughout the 1990s, Tanzi expanded his scope by identifying genes associated with various neurological disorders. In 1993, he discovered the gene responsible for Wilson’s disease and contributed mapping data to identify the SOD1 gene linked to amyotrophic lateral sclerosis. In 1995, he collaborated with Peter Hyslop and Jerry Schellenberg to discover the presenilin 1 and presenilin 2 genes. These three familial early-onset Alzheimer’s disease genes remain critical drug targets. Later, through the Alzheimer’s Genome Project, he identified additional genes including CD33, which plays a significant role in neuroinflammation and microglial function.
Innovation in Disease Modeling
In 2014, Tanzi and his team introduced a three-dimensional cell culture organoid system often referred to as Alzheimer's-in-a-Dish. This innovation allowed for the first in vitro observation of amyloid plaque formation and its subsequent role in causing neurofibrillary tangles, a process that proved difficult to replicate in mouse models. This human stem cell-based technology has significantly enhanced the efficiency of drug screening for potential Alzheimer’s treatments. Furthermore, he developed gamma-secretase modulators, a class of compounds designed to address amyloid plaque deposition without inhibiting enzyme function.
Academic and Professional Standing
Tanzi currently serves as the director of the Genetics and Aging Research Unit and the Henry and Allison McCance Center for Brain Health at Massachusetts General Hospital. He has authored over 800 research papers and maintains membership in the National Academy of Medicine. His professional contributions have been recognized with numerous accolades, including the 1996 Potamkin Prize and the Metropolitan Life Award. In 2015, he was featured on the TIME100 Most Influential People in the World list.
Fast facts
- Born: 1958, Providence
- Education: University of Rochester (B.S., B.A.), Harvard Medical School (Ph.D.)
- Primary Affiliation: Harvard University
- Notable Award: Potamkin Prize (1996)
- Research Focus: Genetics of neurological disease
- Key Discovery: APP, PSEN1, and PSEN2 genes
- Innovation: Alzheimer's-in-a-Dish organoid model
- Publications: Over 800 research papers
Questions readers ask
What is the function of the CD33 gene in Alzheimer's research?
CD33 encodes a cell-surface receptor on microglial cells that can inhibit phagocytosis and induce neuroinflammation when overexpressed.
What is the significance of the Alzheimer's-in-a-Dish model?
It is a 3-D human stem cell organoid system that allows researchers to observe how amyloid plaques directly lead to the formation of neurofibrillary tangles.
Achievements
- Potamkin Prize — 1996
- Notable work: Amyloid β Protein Gene: cDNA, mRNA Distribution, and Genetic Linkage Near the Alzheimer Locus
- Held posts at Harvard University
- Fields: genetics
